allogeneic γδT cells

Allogeneic γδT cells are a form of cell therapy in which gamma delta (γδ) T lymphocytes are isolated from healthy donors, expanded ex vivo, and administered to patients as an "off-the-shelf" immunotherapy. Unlike conventional αβ T cell therapies that require patient-specific manufacturing (autologous), these products use donor-derived cells that can be given to multiple recipients. The unique biology of γδT cells combines features of both adaptive and innate immunity; they recognize and kill tumor or infected cells in a manner independent of major histocompatibility complex (MHC), reducing the risk of graft-versus-host disease (GvHD). This MHC-independence allows for safe administration across HLA barriers. Mechanistically, allogeneic γδT cell therapies exert antitumor effects through direct cytotoxicity against malignant or stressed target cells via their native receptors and natural killer-like activity. They do not require prior antigen sensitization or presentation by MHC molecules. These properties make them promising for treating hematological malignancies such as acute myeloid leukemia (AML), B-cell lymphoma, neuroblastoma, and solid tumors. Several companies have developed proprietary platforms to expand these donor-derived γδT cell populations under GMP conditions for clinical use[1][4][5][6][7][8][9].

Other names

allogeneic gamma delta T cellsallogeneic γδ T lymphocytesdonor-derived γδT cells